article thumbnail

Leading pharmaceutical compounding companies in contract marketing

Pharmaceutical Technology

Increasing drug failure rates and essential drug shortages have driven the growth of the compounding pharmacies market, which has a high growth potential, especially in emerging economies. It may provide access to discontinued drugs and allows for alternative compounded dosage forms.

Marketing 130
article thumbnail

Enzalutamide by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Hormones 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

University of Illinois at Chicago's new breast cancer drug is safe and can halt disease progression, according to a Phase 1 trial

The Pharma Data

A new breast cancer drug, called TTC-352, can halt the spread of the disease and is safe according to a Phase 1 clinical trial. The drug is being developed and tested by researchers at the University of Illinois at Chicago and is a type of hormone therapy, which targets oestrogen receptor-positive types of breast cancer.

article thumbnail

Enzalutamide by Pfizer for Myelofibrosis: Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Myelofibrosis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Hormones 100
article thumbnail

Enzalutamide by Pfizer for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Hormones 100
article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients.

Insulin 128
article thumbnail

Acella Pharmaceuticals voluntarily recalls thyroid drugs over lack of potency

The Pharma Data

Acella Pharmaceuticals is recalling two types of its thyroid medication as the drugs may be too weak to properly treat those who take them. . Acella has received four reports of adverse events that were related to these drugs, which are sold in 100 tablet bottles with expiration dates of October and November 2020.